There are additional reports that AKR1C4 and ADCY5 are hub genes that may be independent prognosis biomarkers and therapeutic targets for CRC patients (Gylfe et al., 2013; Yang, Zhang & Yang, 2019), which was consistent with our results. Here, ADCY5 is linked to colorectal carcinoma.